Shortly after taking reins at BioMarin, CEO Alexander Hardy laid out three paths the company could take for its struggling ...

Novartis has started to feel the squeeze from generics to its top-selling drug, heart therapy Entresto. | Novartis has ...

The FDA has slammed generic drug maker Hetero Labs with a Form 483 after an inspection of one of its warehouses in India ...

In its mission to enlighten others to the symptoms of obstructive sleep apnea (OSA), Eli Lilly is getting an assist from NBA ...

The FDA has issued another complete response letter (CRL) to Regeneron, rejecting its bid for approval of its prefilled syringe version of high-dose (HD) Eylea—again for unresolved issues at the ...

Citing insurance claims data, CSL’s leaders said they expect this season's flu vaccination rates in the U.S. to decline by 12% overall and by 14% for people ages 65 and older compared with last year.

With new digs in Tampa, Florida, now open and the one-year anniversary of its $16.5 billion acquisition fast approaching, ...

Some four years into its run as an independent women’s health outfit, Organon is parting ways with its first CEO after an ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

More and more, as momentum builds for the soon-to-be-blockbuster Winrevair, Merck’s $11.5 billion buyout of Acceleron in 2021 is looking like a savvy move. | Paving the way for the label update were ...

AstraZeneca and Organon have been found in serious breach of the U.K.’s pharma code, with a watchdog ruling both companies ...

Just as pharmaceutical tariff uncertainty seemed to be easing in the U.S., the Trump administration is reportedly staging a ...